 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
HEMOSOL CORP, (HMSL) Stock Rating Learn More
| Our Overall Rating on HEMOSOL CORP, HMSL is Not Available | | Hemosol Corp., an integrated biopharmaceutical company, engages in the development of a family of products for the treatment of human hemoglobin deficiencies. It also discovers and develops an array of products derived from human blood proteins. The company develops a range of products, including its principal oxygen therapeutic product, HEMOLINK, a purified, human-derived oxygen therapeutic product. Hemosol is also developing additional therapeutics and a hemoglobin-based delivery platform to treat diseases, such as hepatitis C and cancers of the liver, as well as a cell therapy for the treatment of cancer through its cell expansion and stem cell research activities. The company has strategic alliances with ProMetic Life Sciences, Inc. and the American Red Cross. Hemosol was incorporated in February 2004 and is headquartered in Mississauga, Ontario. | | Our Not Available Rating on HMSL was issued on 12/02/2008 |
HEMOSOL CORP Technical Rating
|
|
|
|
